Podcasts about innoviva

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into the latest breakthroughs, regulatory updates, and industry trends shaping the future of healthcare.Let's start with Johnson & Johnson's recent achievement in precision oncology. They've secured a second FDA approval for Akeega, a combination therapy that merges J&J's Zytiga with GSK's Zejula. This innovative approach targets BRCA2-mutated metastatic castration-sensitive prostate cancer, marking a significant advancement in personalized medicine. This approval not only highlights the progress in tailored treatment strategies but also sets a new benchmark for therapeutic innovation in this particular cancer subset.Moving on to cardiovascular health, Cincinnati's LIB Therapeutics has introduced Lerochol, a third-generation PCSK9 inhibitor designed to lower cholesterol. Unlike its predecessors, Lerochol offers simplified administration, potentially improving patient adherence and outcomes. This approval is part of a broader effort to refine lipid-lowering therapies and better address cardiovascular diseases.In a groundbreaking development for heart rhythm disorders, Milestone Pharmaceuticals has received FDA approval for Cardamyst, a nasal spray that patients can self-administer to manage paroxysmal supraventricular tachycardia (PSVT). This novel treatment option empowers patients with an on-demand solution to control their heart rhythms, significantly enhancing their quality of life.Turning to infectious diseases, Innoviva's Nuzolvence has been approved as a much-needed new treatment for gonorrhea, the first in over three decades following GSK's Blujepa. This marks an essential step forward in combating antibiotic-resistant sexually transmitted infections and highlights the urgency of developing new antimicrobial agents.However, not all ventures have met with success. Argenx recently halted studies of its drug Vyvgart in thyroid eye disease after disappointing trial results. This decision underscores the inherent challenges and risks involved in drug development, particularly when tackling complex autoimmune conditions.Sanofi has faced its own hurdles with Tolebrutinib after experiencing both FDA delays and trial misses in non-relapsing secondary progressive multiple sclerosis. These setbacks emphasize the intricacies of bringing innovative therapies to market and the critical importance of robust clinical trial design and regulatory strategy.Strategic collaborations are also playing a pivotal role in the industry. Adaptive Biotechnologies has partnered with Pfizer to leverage its T-cell receptor discovery technology. Meanwhile, Dren Bio is expanding its collaboration with Sanofi to develop next-generation B-cell depleting therapies for autoimmune diseases. These alliances reflect an increasing trend towards collaborative innovation to harness cutting-edge technologies.Another strategic move comes from Sobi, which has acquired Arthrosi Therapeutics for $950 million to bolster its portfolio with phase 3 gout treatments. This acquisition bypasses traditional IPO routes and showcases evolving deal-making strategies within biopharma.In another exciting development, Kyverna Therapeutics is on the verge of securing the first-in-class CAR-T therapy approval for autoimmune diseases following promising trial results with its CD19 agent. This could herald a new era in autoimmune disease management through cellular therapies.In regulatory news beyond pharmaceuticals, former President Donald Trump signed an executive order establishing a unified federal framework for artificial intelligence (AI). This aims to streamline AI regulation across states and could accelerate AI integration into various sectors, including healthcare.These developments collectively represent pivotal moments in the pharmaceutical and Support the show

Within the last few days, there has been breaking news regarding the war on gonorrhea. Nuzolvence (zoliflodacin) was FDA approved on December 13, 2025, and Blujepa (gepotidacin) was FDA approved on December 11, 2025.These new oral treatments are particularly important given the global rise in gonococcal drug resistance and the convenience they offer over injectable options, potentially improving patient adherence and public health outcomes. Listen in for details. 1. FDA News Release. FDA Approves Two Oral Therapies to Treat Gonorrhea. fda.gov2. Innoviva Specialty Therapeutics. U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-Dose Oral Antibiotic, for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents. innovivaspecialtytherapeutics.com3. CNN. New gonorrhea treatments approved by FDA for first time in decades. 4. The New York Times. F.D.A. Approves Two New Drugs to Treat Gonorrhea. 5. STAT. FDA approves zoliflodacin, a gonorrhea pill marketed as Nuzolvence. 6. Fierce Pharma. FDA endorses another gonorrhea treatment, blessing Innoviva's Nuzolvence.

Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding of the industry's evolution and the pivotal roles he played at Theravance, Merck, and J&J. The episode delves into the significance of intracellular protein interactions and FogPharma's focus on developing helicon peptides to address this unmet need. Dr. Mammen's emphasis on a moonshot culture at FogPharma, coupled with his strategic approach to commercial success in biotech, makes this episode essential listening for executives in the biotech industry who are looking to stay ahead of future trends and gain insights into the innovative approaches shaping the industry's landscape. His profound knowledge and experience position him as a thought leader, offering invaluable perspectives on the challenges and opportunities in biotech, making this episode a compelling resource for industry executives seeking to implement strategies for commercial success in the biotech sector. Biography: Mathai Mammen is a world-renowned innovator in drug discovery, development, and team and company building. He brings significant global R&D and corporate leadership experience to his role as CEO, President and Chairman at FogPharma. Most recently, Mathai was a member of the executive committee at Johnson & Johnson, where he served as executive vice president of pharmaceuticals, R&D. During his tenure, he spearheaded a significant evolution of Janssen's R&D, one of the largest R&D organizations in the world. Mathai was a key leader in Johnson & Johnson's bold foray into COVID vaccines and he helped drive Janssen's substantial growth to become one of the top pharmaceutical companies globally. Under Mathai's leadership, Janssen R&D executed 40+ acquisitions and licenses and 350+ strategic partnerships and collaborations. A central pillar of his strategy was data science, which he used to couple recent revolutionary advances in data, compute and algorithmic approaches to every aspect of discovering and developing medicines. Mathai led his team to global approvals of eight new medicines, including Tremfya™, Darzalex Faspro™, Balversa™, Carvykti™, Rybrevant™, Ponvory™, Spravato™ and Tecvayli™, with many additional global approvals for expanded indications of marketed products. Prior to his role at Johnson & Johnson, Mathai served as senior vice president at Merck, where he was responsible for multiple research areas, including cardiovascular, metabolic and renal diseases, immunology, oncology and immuno-oncology. Before Merck, he led R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides. Under his leadership, Theravance advanced a robust pipeline of multiple development-stage compounds resulting in five approved pharmaceutical products, and separated into two companies: Theravance Biopharma, Inc. and Innoviva, Inc. In addition to his extensive corporate experience, Mathai currently serves on the board of directors of 10x Genomics, Inc. He has authored more than 150 peer-reviewed publications and patents. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalistinnen Anja Ettel und Jana Sepehr über den Montags-Blues im Dax, eine Breitseite für Siemens und große Hoffnungen durch Big Pharma. Außerdem geht es um Biontech, Nasdaq China Index, GSK, Daimler Truck, Covestro, Mercedes-Benz Group, Siemens, Uniper, Deutsche Bank, Sartorius Vz, Nordex, RWE, Klarna, Twitter, Netflix, Meta, Amazon, Sanofi, Novartis, Pfizer, Entavis, Innoviva, Merck und ishares MSCI World Healthcare Sector ESG ETF (WKN: A2PHCD). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Straight from Benzinga newsdesk, hosts Brent Slava and Steve Krause bring you the market news and stocks to watch.On Fridays Benzinga's resident Options Expert Ryan Faloona joins us to spice things up.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659DWAC - reminder: PHUN and CFVI have traded closely with DWAC. these 3 stocks can be considered "Trump plays." CFVI is spac for Rumble video platform (which Trump has used in the past) and PHUN previously had a deal where Trump's campaign was using the company's software service. something interesting to mention: SNAP hasn't been very sensitive to TWTR/Musk news.JPM - other notable earnings dates in July: MS Thursday, C, WFC Friday, GS, BAC next week Monday, IBM Monday, NFLX Tues next week, TSLA Wed, UAL Wed, SNAP Thurs, Jul. 21, AAPL will be the last week in Jul., probably the 26th or 27thBGNE - how does the FDA panel work? when will we hear results?Today's 5 Stock Ideas:Digital World Acquisition Corp. (DWAC) - A play on competition (or a lack of competition) in the social media space. Big news in the space over the weekend was that Elon Musk terminated his deal to buy Twitter (TWTR). Shares of Digital World, the special purpose acquisition corporation (SPAC) that will merge with Trump Media and its Truth Social social media platform, were up about 15% on the report.JP Morgan (JPM) - Will kick off the big bank earnings season on Thursday of this week. Investors can expect JP Morgan's results to be out before 7 a.m. EDT on Thursday.Roblox (RBLX) - A play on some positive analyst commentary on Friday of last week. Data-driven research firm, M Science, issued a note that suggested Roblox's could be seeing a strong rebound in year-over-year bookings, a key metric for the company's investors.Innoviva (INVA) - A play on consolidation in the pharma space. Innoviva announced it will buy La Jolla Pharma (LJPC) in about a $150 million deal, or about $6.23 per share.Beigene (BGNE) - A play on an upcoming FDA date. An FDA panel is scheduled to review Beigene's esophageal squamous cell carcinoma treatment candidate on Tuesday of this week.Hosts:Steve Krause Reach out to Steve at stevekrause@benzinga.comSr. Reporter Benzinga NewsdeskBrent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga NewsdeskRyan Faloona Reach out to Ryan at ryanfaloona@benzinga.comDirector of Customer Successpro.benzinga.comFree 2-week trial, no credit card requiredUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

After a brief hiatus, my stock dissection series continues with Innoviva, a company with a portfolio of royalties and other healthcare assets. 

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

In the late nineties, a company named "Advanced Medicine" came together with the 4Cs of entrepreneurship in place: a concept, co-founders, capital, and some well-placed cold-calls. Mathai Mammen was one of those co-founders, still living in a dorm at the time. The company's investors evolved, it renamed itself, went public, and ultimately split into two independent companies: Innoviva (INVA) and Theravance Biopharma (TBPH). Today, Mathai is the SVP of R&D at Theravance Biopharma. Under his leadership, they have always done things a little differently. In the beginning they used their seed capital to build an in-house vivarium. They have discovered all of their development candidates - 31 and counting - internally or collaboratively. And after 3 approvals, they left their royalty stream to Innoviva and struck out on their own to focus on R&D - because "it's difficult to be innovative when you're in the shadows." Mathai has had a longstanding reputation as one of the good guys in the industry, but in recent years he has doubled down. After two extraordinary family tragedies, he calls out the importance of persistence, humility, and empathy above all - both in and outside of business.